PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New clinical trial to test novel approach to treat triple-negative breast cancer

Experimental drug may help reprogram tumor cells to respond to hormone therapy

New clinical trial to test novel approach to treat triple-negative breast cancer
2011-06-03
(Press-News.org) Baltimore, MD -- A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein called an estrogen receptor to make them sensitive to hormone therapy.

Saranya Chumsri, M.D., an oncologist at the Greenebaum Cancer Center and assistant professor of medicine at the University of Maryland School of Medicine, is the principal investigator of the newly opened National Cancer Institute-funded study. The trial is based on laboratory studies by Angela H. Brodie, Ph.D., an internationally recognized University of Maryland breast cancer researcher, and her colleagues. Their research, recently published in the journal Cancer Research, found that entinostat can cause triple-negative breast cancer cells to become sensitive to a hormone therapy such as an aromatase inhibitor. Dr. Brodie pioneered the development of aromatase inhibitors, a class of breast cancer drugs that reduces the level of estrogen produced by the body, thereby cutting off the fuel to cancer cells.

In this Phase II trial, doctors will treat newly diagnosed postmenopausal patients with entinostat and an aromatase inhibitor called anastrozole (Arimidex) before they have surgery to remove their cancer. Researchers will analyze tissue from the tumor and blood samples to evaluate whether the treatment is effective. After surgery, patients will receive standard treatment, such as chemotherapy and radiation.

"We hope that entinostat will make the tumor cells more sensitive to the drug anastrozole, causing the tumor to shrink or, at the very least, stop growing," Dr. Chumsri says. "For patients with triple-negative breast cancer, chemotherapy is currently the only drug treatment option, and it has a lot of side effects compared to hormone therapies like anastrozole."

Triple-negative breast cancer is unique in that it lacks three common receptors in the cell – estrogen, progesterone or human epidermal growth factor 2 (HER2), which are the targets of drugs widely used today to treat breast cancer. As a result, this cancer can be very difficult to treat; it doesn't respond to therapies that target estrogen and progesterone receptors, such as tamoxifen (Nolvadex), fulvestrant (Faslodex) and aromatase inhibitors (Femara, Arimidex and Aromasin), or to HER2-targeted therapies such as trastuzumab (Herceptin) and lapatinib (Tykerb).

About 15 to 20 percent of breast cancers are triple-negative. For unknown reasons, there is a higher prevalence of this type of breast cancer among African-Americans, young women and women with the BRCA1 gene mutation. African-American women are twice as likely as white women to have this type of cancer, which can be very aggressive and spread to other parts of the body, such as the lungs, liver and brain.

The clinical trial is based on laboratory studies by Dr. Brodie, a professor of pharmacology and experimental therapeutics, and Gauri J. Sabnis, Ph.D., an assistant professor of pharmacology and experimental therapeutics, at the University of Maryland School of Medicine, in collaboration with Saraswati Sukumar, M.S., Ph.D., a professor of oncology and pathology at the Johns Hopkins University School of Medicine. Their research showed that entinostat can sensitize triple-negative breast cancer cells to treatment with an aromatase inhibitor, and when combined with an aromatase inhibitor, also reduce the growth and spread of tumors in animal models.

"Adding to her long list of remarkable achievements, Dr. Brodie has continued her research into aromatase inhibitors, searching for ways to overcome tumors' resistance to treatment," says E. Albert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the University of Maryland School of Medicine. "This multicenter clinical trial led by Dr. Saranya Chumsri is an excellent example of how our scientists turn discoveries made in the lab into new treatments that may benefit patients."

Entinostat is an oral, selective histone deacetylase (HDAC) inhibitor. This anti-cancer agent is being developed by Syndax Pharmaceuticals, Inc., and is being investigated in other clinical studies for the treatment of advanced estrogen receptor-positive breast cancer, advanced non-small-cell lung cancer, advanced colorectal cancer and Hodgkin's lymphoma.

Triple-negative breast cancer patients in this clinical trial will take entinostat weekly and anastrozole once daily for two to four weeks while they are waiting to have surgery. Researchers will use blood tests and tissue analysis of tumors to evaluate the effectiveness of the combination therapy.

Researchers hope to enroll a total of 41 patients at 20 sites, including the University of Maryland Greenebaum Cancer Center. The centers involved in the study are affiliated with the University of Chicago Phase II study research consortium and the California Cancer Consortium.

Dr. Chumsri says that if the results of this trial are positive, researchers plan to launch a larger study to test the combination therapy on women whose cancer has metastasized to other parts of the body. "These women have limited treatment options. Hopefully, this treatment would give them a longer period in which their cancer is not progressing, with only minimal side effects compared to chemotherapy," she says.



INFORMATION:



You can view related resources here.

[Attachments] See images for this press release:
New clinical trial to test novel approach to treat triple-negative breast cancer

ELSE PRESS RELEASES FROM THIS DATE:

It is Vexing to be Hexed by Allegations of Sexual Misconduct: Sex Crimes and Use of Legal Counsel

2011-06-03
In Michigan, there are four degrees of criminal sexual misconduct: the first degree is the most serious and covers a range of illegal activities, which is punishable by up to life in prison. The second and third degrees cover lesser activities which are punishable by up to 15 years imprisonment. Finally, the fourth degree covers acts punishable by up to 2 years imprisonment and/or a fine of $500.00. However, criminal sexual misconduct is not the only crime of its nature involved with the legal system. Acts such as juvenile and adult sex offenses, sexting (using a cell phone ...

Therapies to improve biochemical functions hold promise as treatments for autism

2011-06-03
Two promising new treatments to aid people with autism have shown effectiveness in pilot studies conducted by an Arizona State University professor and private researchers. Several studies indicate that children with autism often have abnormalities in critical biochemical functions that help maintain health – specifically methylation, glutathione, and mitochondrial functions. Methylation turns proteins in the body on and off – including DNA and RNA – a function that controls gene activity. Glutathione, a primary antioxidant, provides a defense against toxic metals ...

Phoenix Coyotes Bankruptcy: A Far Cry From Consumer Bankruptcy

2011-06-03
American companies frequently use the bankruptcy process to reorganize and help a business survive through difficult economic times. For similar reasons, Chapter 7 bankruptcy and Chapter 13 bankruptcy make sound financial sense for individuals and married couples who have fallen behind due to mounting debts caused by medical expenses, job loss and other difficulties. One of the most notorious recent corporate bankruptcies in Arizona involves the local National Hockey League franchise, the Phoenix Coyotes. Since moving from Winnipeg in 1996, the club has not had a great ...

Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011

2011-06-03
To arrange for an interview with a researcher, please contact the Communications and External Relations staff member identified at the end of each tip. For more information on ORNL and its research and development activities, please refer to one of our Media Contacts. If you have a general media-related question or comment, you can send it to news@ornl.gov. TRANSPORTATION -- Screening for safety . . . Unsafe commercial motor vehicles may be off the roads sooner with help from an Oak Ridge National Laboratory-led testing facility in Greene County, Tenn. ORNL researchers ...

Managing forests requires a bird's-eye view

Managing forests requires a birds-eye view
2011-06-03
Managers of northern Michigan forests may not see the birds for the trees – or at least are in danger of losing sight of songbird neighborhoods when looking out for timber harvests. In a novel look at managing both the future's timber harvest while being mindful of the impact on key songbirds in Michigan's Upper Peninsula, Michigan State University researchers use a new forest simulation model for the first time to look at what timber-friendly hardwood regeneration can mean to bird habitat. And it's a long-range look, given that the time lag between forest management ...

Illinois Drugged-Driving Law: Unbending and Complex

2011-06-03
Illinois drugged-driving law is very tough to beat if you are charged with a violation. On April 21, 2011, the Supreme Court of Illinois in People v. Martin clarified important aspects of that law. Because the Supreme Court does not often decide DUI-drug cases, Illinois criminal defense attorneys and law enforcement are taking a close look at this major court opinion. Basically, Martin enunciates that four of the six provisions of the law require that to be guilty of alcohol or drugged driving the prosecution must prove that the ingestion of alcohol or drugs caused ...

Spartanburg Hotel Provides Nearby Lodging to Guests Attending the Creative Taste of Spartanburg

2011-06-03
Hampton Inn Spartanburg - North I-85, a premier Spartanburg SC hotel, offers nearby accommodations to attendees of the Creative Taste of Spartanburg. The event will be held on Saturday, June 11, 2011 from 5-10pm in downtown Spartanburg. Vendors will set up west of Morgan Square and the Clock Tower on Ezell Street, King Street, W. Main Street, and Daniel Morgan Avenue. Admission to the event is free. Attendees of the Creative Taste of Spartanburg will be able to purchase food and beverages from some of Spartanburg's most popular restaurants. Wine tastings will be offered ...

Small change makes a big difference for ion channels

Small change makes a big difference for ion channels
2011-06-03
CHAMPAIGN, Ill. — Using a high-resolution single-molecule study technique, University of Illinois researchers have seen the very subtle differences between two branches of an important family of neurotransmitter-gated ion channels. Professor Claudio Grosman and research scientist Gisela Cymes published their work in the journal Nature. Nicotinic-type receptors are proteins embedded in the membranes of nerve and muscle cells that regulate activity. A neurotransmitter, such as acetylcholine, triggers a small conformation change in the protein that opens a channel and ...

Phase change memory-based 'moneta'system points to the future of computer storage

Phase change memory-based monetasystem points to the future of computer storage
2011-06-03
A University of California, San Diego faculty-student team is about to demonstrate a first-of-its kind, phase-change memory solid state storage device that provides performance thousands of times faster than a conventional hard drive and up to seven times faster than current state-of-the-art solid-state drives (SSDs). The device was developed in the Computer Science and Engineering department at the UC San Diego Jacobs School of Engineering and will be on exhibit June 7-8 at DAC 2011, the world's leading technical conference and trade show on electronic design automation, ...

Northern Rock Launches New Issue of its Easy Access Online Saver

2011-06-03
Northern Rock has announced the launch of the latest issue of its easy access savings account for customers wishing to manage their funds exclusively online. E-Saver (Issue 6) is available now and pays 2.75% gross* pa/AER**. The new Northern Rock savings account can be opened with an initial investment of GBP1 and E-Saver (Issue 6) allows subsequent deposits from as little as GBP1. The account allows a balance of up to GBP100,000 and account holders can choose to have their interest paid either annually on 11 March or monthly (on 10th of the month. Monthly gross* is ...

LAST 30 PRESS RELEASES:

New way to find “aged” cells marks fresh approach for research into ageing

From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New method to study catalysts could lead to better batteries

Current Molecular Pharmacology impact factor rises to 2.9, achieving Q2 ranking in the Pharmacology & Pharmacy category in 2024 JCR

More time with loved ones for cancer patients spared radiation treatment

New methods speed diagnosis of rare genetic disease

Genetics of cardiomyopathy risk in cancer survivors differ by age of onset

Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism

Targeting fusion protein’s role in childhood leukemia produces striking results

Clear understanding of social connections propels strivers up the social ladder

New research reveals why acute and chronic pain are so different – and what might make pain last

Stable cooling fostered life, rapid warming brought death: scientists use high-resolution fusuline data reveal evolutionary responses to cooling and warming

New research casts doubt on ancient drying of northern Africa’s climate

Study identifies umbilical cord blood biomarkers of early onset sepsis in preterm newborns

AI development: seeking consistency in logical structures

Want better sleep for your tween? Start with their screens

Cancer burden in neighborhoods with greater racial diversity and environmental burden

Alzheimer disease in breast cancer survivors

New method revolutionizes beta-blocker production process

Mechanism behind life-threatening cancer drug side-effect revealed

Weighted vests might help older adults meet weight loss goals, but solution for corresponding bone loss still elusive

Scientists find new way to predict how bowel cancer drugs will stop working – paving the way for smarter treatments

Breast cancer patients’ microbiome may hold key to avoiding damaging heart side-effects of cancer therapies

Exercise-induced protein revives aging muscles and bones

American College of Cardiology issues guidance on weight management drugs

Understanding the effect of bedding on thermal insulation during sleep

Cosmic signal from the very early universe will help astronomers detect the first stars

With AI, researchers find increasing immune evasion in H5N1

Study finds hidden effects of wildfires on water systems

[Press-News.org] New clinical trial to test novel approach to treat triple-negative breast cancer
Experimental drug may help reprogram tumor cells to respond to hormone therapy